<DOC>
	<DOCNO>NCT00492830</DOCNO>
	<brief_summary>This study perform evaluate safety tolerability TRC093 antibody .</brief_summary>
	<brief_title>Phase 1 , Open-label , Dose Escalation Study TRC093 , Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>In addition safety , study also evaluate pharmacokinetics , tumor response , anti-TRC093 antibody formation .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>A patient eligible study participation follow criterion apply : 1 . The patient give informed consent . 2 . The patient willing able abide protocol . 3 . The patient least 18 year old . 4 . The patient advance cancer eligible treatment effective treatment exists . 5 . Significant toxicity result prior therapy must recover . 6 . If patient female childbearing potential , use acceptable/effective method contraception . 7 . If patient female , negative serum pregnancy test within past 30 day . 8 . The patient adequate ability perform activity daily live . 9 . The patient adequate organ function assess laboratory test A patient eligible study participation follow criterion apply : 1 . The patient weigh 264 lb . 2 . The patient major surgical procedure , significant injury within past 28 day anticipation need major surgery course study . 3 . The patient receive treatment cancer , include radiation ( minimal amount localize radiation may allow ) , within past 28 day . 4 . The patient know brain tumor . 5 . The patient experience blood clot within six month prior study start . 6 . The patient nonhealing wound , ulcer bone fracture . 7 . The patient receive recent thrombolytic anticoagulant therapy . 8 . The patient unstable medical condition significant comorbid pathophysiology ( e.g . active infection , poorly control diabetes , unstable angina , severe heart failure ) would interfere his/her participation study . 9 . The patient enrol , plan enroll , concurrent treatment protocol another investigational product . 10 . The patient receiving , plan receive , anticancer therapy study exception patient receive chronic luteinizing hormonereleasing hormone ( LHRH ) agonists .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>TRC093</keyword>
	<keyword>denature collagen</keyword>
	<keyword>solid tumor</keyword>
	<keyword>antibody</keyword>
	<keyword>TRACON</keyword>
	<keyword>Locally advanced solid tumor</keyword>
	<keyword>Metastatic solid tumor</keyword>
</DOC>